Events After the End of the Reporting Period
On April 6, 2017, Bayer decided to terminate its option right relating to the late-stage development and commercialization of biopharmaceutical Wnt pathway inhibitors under its collaboration with OncoMed Pharmaceuticals Inc., United States. In this connection, impairment losses of €69 million were recognized at the start of the second quarter of 2017.
Repayment of financial liabilities
On April 5, 2017, Bayer Holding Ltd., Japan, repaid on schedule a bond with a nominal volume of JPY 30 billion.
Leverkusen, April 25, 2017
The Board of Management
Dr. Hartmut Klusik